Spots Global Cancer Trial Database for classic hodgkin lymphoma
Every month we try and update this database with for classic hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | NCT05179603 | Classic Hodgkin... Diffuse Large B... | THOR-707 Pembrolizumab | 12 Years - | Sanofi | |
| Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD) | NCT06235047 | Classic Hodgkin... | 60 Years - | Federico II University | ||
| Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | NCT03712202 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... Lymphocyte-Rich... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Bleomycin Brentuximab Ved... Dacarbazine Doxorubicin Nivolumab Quality-of-Life... Vinblastine | 16 Years - | City of Hope Medical Center | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | NCT01771107 | AIDS-Related Ho... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... HIV Infection | Brentuximab Ved... Dacarbazine Doxorubicin Hyd... Pharmacological... Vinblastine | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | NCT03233347 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... | Brentuximab Ved... Dacarbazine Doxorubicin Laboratory Biom... Nivolumab Vinblastine | 18 Years - 60 Years | Academic and Community Cancer Research United | |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | NCT05955105 | Head and Neck C... Cervical Cancer Endometrial Can... Triple Negative... Ovarian Cancer Soft Tissue Sar... Melanoma Nasopharyngeal ... Non Small Cell ... Classic Hodgkin... | ILB-2109 Toripalimab | 18 Years - 80 Years | Innolake Biopharm | |
| Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | NCT00654732 | Classic Hodgkin... Lugano Classifi... Lugano Classifi... | Bleomycin Dacarbazine Doxorubicin Hyd... Rituximab Vinblastine | 17 Years - | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | NCT02166463 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Childhood Hodgk... Classic Hodgkin... | Bleomycin Sulfa... Brentuximab Ved... Cyclophosphamid... Doxorubicin Hyd... Etoposide Laboratory Biom... Methylprednisol... Pharmacological... Prednisone Quality-of-Life... Questionnaire A... Vincristine Sul... | 2 Years - 22 Years | National Cancer Institute (NCI) | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | NCT06164275 | Classic Hodgkin... | Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine | 18 Years - | Northwestern University | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | NCT06164275 | Classic Hodgkin... | Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine | 18 Years - | Northwestern University | |
| Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | NCT05949931 | Classic Hodgkin... | Concurrent penp... Sequential penp... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | NCT05955105 | Head and Neck C... Cervical Cancer Endometrial Can... Triple Negative... Ovarian Cancer Soft Tissue Sar... Melanoma Nasopharyngeal ... Non Small Cell ... Classic Hodgkin... | ILB-2109 Toripalimab | 18 Years - 80 Years | Innolake Biopharm | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | NCT06164275 | Classic Hodgkin... | Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine | 18 Years - | Northwestern University | |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | NCT03907488 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... Lymphocyte-Rich... | Biospecimen Col... Brentuximab Ved... Computed Tomogr... Dacarbazine Doxorubicin Hyd... Filgrastim Magnetic Resona... Nivolumab Pegfilgrastim Positron Emissi... Quality-of-Life... Questionnaire A... Radiation Thera... Vinblastine Sul... | 12 Years - | National Cancer Institute (NCI) | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | NCT05179603 | Classic Hodgkin... Diffuse Large B... | THOR-707 Pembrolizumab | 12 Years - | Sanofi | |
| A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | NCT03722147 | Hodgkin's Lymph... | AK105 | 18 Years - | Akeso |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
